Bliss Gvs Pharma LimitedNSE: BLISSGVS

BLISSGVS: Revenue up, net profit down; subsidiary sale and dividend declared, restructuring ahead

· Issued by Bliss Gvs Pharma Limited

Revenue grew year-over-year, but consolidated net profit declined due to lower margins and exceptional items. Board approved sale of a step-down subsidiary and asset, and recommended a final dividend, with restructuring expected to impact H1 FY26.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.